From China With Discount? BeiGene Moves Towards First Global PD-1 Green Light
But Price, Competition Looming Hurdles Amid US Filing
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.
You may also be interested in...
Novartis has filed the PD-1 inhibitor tislelizumab, licensed from BeiGene, for second-line esophageal cancer with the FDA, the first submission outside China for the closely-watched therapy.
Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.
Hengrui’s second major in-licensing deal this year is the latest example of the Chinese pharma innovation darling’s eagerness for new assets, particularly as some of its other products come under pressure.